Kara L. Davis

Apr 6, 2023 | nature.com | Karin Straathof |Tom Davidson |Kara L. Davis |Juliane Gust |Michael Lim |Robbie G. Majzner | +6 more

AbstractCancer immunotherapies have unique toxicities. Establishment of grading scales and standardized grade-based treatment algorithms for toxicity syndromes can improve the safety of these treatments, as observed for cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) in patients with B cell malignancies treated with chimeric antigen receptor (CAR) T cell therapy.